izalontamab brengitecan + PD-1 monoclonal antibody

Izalontamab brengitecan + PD-1 monoclonal antibody is an experimental combination therapy intended for cancer treatment, typically in solid tumors such as non-small cell lung cancer. Izalontamab brengitecan (also known as iza-bren, BL-B01D1) is an antibody-drug conjugate composed of an EGFR × HER3 bispecific antibody conjugated to a novel topoisomerase I inhibitor payload via a cleavable linker[1][3][5]. PD-1 monoclonal antibodies are immune checkpoint inhibitors that block the PD-1 receptor on T cells, thereby enhancing anti-tumor immune responses[2][4]. This combination aims to synergistically inhibit tumor cell proliferation through both direct cytotoxicity and immune-mediated mechanisms. The combination is under clinical evaluation for advanced cancers, especially in the setting of EGFR-mutant non-small cell lung cancer.

Brand names

iza-bren

Other names

iza-bren + PD-1 monoclonal antibody